Antisense Therapeutics Ltd (ASX:ANP) is an Australia-based company developing and commercialising antisense pharmaceuticals.
Antisense Therapeutics Limited (ASX:ANP) is preparing to outline details in relation to the ATL1103 program for multiple sclerosis.
Antisense has been granted a trading halt to prepare, with its shares placed in pre-open.
The halt will remain in place until the opening of trade on Wednesday 9th March 2016, or earlier if an announcement is made to the market.
Proactive Investors is a global leader reporting financial news, media, research and hosts events for listed emerging growth companies and investors across four continents.